Why Is Biogen Stock Falling Thursday?

Biogen Inc. (NASDAQ:BIIB) on Thursday reported topline Phase 2 results for diranersen (BIIB080), its investigational tau-targeting antisense oligonucleotide therapy for early Alzheimer’s disease, highlighting cognitive benefits and reductions in tau biomarkers despite...